Free shipping on all orders over $ 500

Flumatinib

Cat. No. M22326

All AbMole products are for research use only, cannot be used for human consumption.

Flumatinib Structure
Synonym:

HHGV678

Size Price Availability Quantity
5mg USD 90  USD90 In stock
10mg USD 115  USD115 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively. Flumatinib (HH-GV-678) can predominantly inhibit the autophosphorylation of Bcr-Abl in K562 cell. In higher concentration, Flumatinib can inhibit the phosphorylation of c-Kit in Mo7e cell and the phosphorylation of PDGFR in Swiss3T3 cell, however, Flumatinib has no or little effect on other tyrosine kinase including EGFR, KDR, c-Src and HER2.

Chemical Information
Molecular Weight 562.59
Formula C29H29F3N8O
CAS Number 895519-90-1
Solubility (25°C) DMSO 80 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Li Zhang, et al. Clin Cancer Res. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study

[2] Jiangfei Chen, et al. Pharmazie. Metabolic interactions between flumatinib and the CYP3A4 inhibitors erythromycin, cyclosporine, and voriconazole

[3] Si-Man Huang, et al. Clin Case Rep. Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report

[4] Hua Gao, et al. Indian J Hematol Blood Transfus. Efficacy of Flumatinib in CML Patients with F359V/C Mutation

[5] Jie Zhao, et al. Cancer Sci. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants

Related Src-bcr-Abl Products
KX2-361

KX2-361 (KX-02) is a Src-kinase and tubulin polymerization inhibitor. KX2-361 shows anti-tumor activity and induces apoptosis of Glioblastoma (GBM) cell. KX2-361 shows good oral bioavailability and readily crosses the BBB in mice.

Risvodetinib

Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against c-Abl1, c-Abl2/Arg with IC50 values of 33 nM, 14 nM, respectively.

SI-2 hydrochloride

SI-2 hydrochloride is a highly promising SRC-3 inhibitor (PPI) with acceptable oral availability, with IC50 values of 3-20 nM for breast cancer cell death.

KB SRC 4 

KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.

Hydroxymethyl dasatinib 

Hydroxymethyl dasatinib (M24), a benzylhydroxy metabolite of Dasatinib, exhibits an IC50 of 46.7nM in K562 CML cells.

  Catalog
Abmole Inhibitor Catalog




Keywords: Flumatinib, HHGV678 supplier, Src-bcr-Abl, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.